On the contrary, inhibition of ACE2 in already infected COVID-19 patients, could be deleterious via the consequent decrease in the production of angiotensin 1–7, which has been demonstrated to play an anti-inflammatory and antifibrotic activity through its receptor (MasR) [7–9]. This evidence concerns the gene ACE2 and COVID-19.